Windtree Therapeutics

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Additionally, the USPTO Has Published the Patent Application for One Group of Windtree's SERCA2a Activators Additionally, the USPTO Has Published the Patent Application for One Group of Windtree's SERCA2a Activators

Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

WARRINGTON, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime.

Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference

New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039 New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise of warrants to purchase 4,808,595 shares of the Company's common stock, par value $0.001 per share (“Common Stock”), in the aggregate.

Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants

WARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq's $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), following the expiration of the initial 180 days period to regain compliance on November 30, 2022.

Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance

Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why

WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.

Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates

Anticipated New Patent Will Add to the Istaroxime Patent Estate and Provide Intellectual Property Protection Until Late 2039 Anticipated New Patent Will Add to the Istaroxime Patent Estate and Provide Intellectual Property Protection Until Late 2039

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

Tritium DCFC Ltd

MicroVision

Selecta Biosciences

Westport Fuel Systems

Hot penny stocks to watch & what happened in the stock market today. The post What The Stock Market Did Today & Top Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What The Stock Market Did Today & Top Penny Stocks To Watch Now

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure ( https://doi.org/10.1002/ejhf.2629 ). Cardiogenic shock is caused by a failing heart resulting in diminished cardiac output to the body and is characterized by very low blood pressure and hypoperfusion to end-organs. It requires urgent treatment and has a high morbidity and mortality. Windtree conducted a study called SEISMiC of istaroxime in patients experiencing early cardiogenic shock due to heart failure.

Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.

Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

WARRINGTON, Pa., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for in-person 1x1 meetings at the upcoming Ladenburg Thalmann Healthcare Conference taking place at the Sofitel Hotel in New York, NY on September 29, 2022.

Windtree to Present at the Ladenburg Thalmann Healthcare Conference

WARRINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022.

Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Avaya Holdings

Neptune Wellness Solutions Inc.

Here's what you need to know about trading penny stocks on August 24th The post Popular Penny Stocks For Your Buy List Today? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks For Your Buy List Today? 3 to Watch

Source: sfam_photo / Shutterstock.com Windtree Therapeutics (NASDAQ: WINT ) is one of the biggest stock movers on Tuesday after announcing a new global licensing agreement for AEROSURF. AEROSURF is the company's treatment for preterm infants with respiratory distress syndrome and may have other applications.

Why Is Windtree Therapeutics (WINT) Stock Up 50%?

Windtree may receive up to $78.9 million in development, regulatory and commercial milestones  plus low double digit royalties Development and all other costs to be assumed by Lee's Pharmaceutical and Zhaoke Pharmaceutical

Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement

WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2022 and provided key business updates.

Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates

Kaspien Holdings Inc.

Sonnet BioTherapeutics

Can these penny stocks climb this week? The post Check These Penny Stocks For Your Watchlist This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These Penny Stocks For Your Watchlist This Week

Positive Data for Istaroxime in Early Cardiogenic Shock

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persisted through 24 hours

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

Call to be held on Monday, May 23rd at 4:30 pm EDT following the Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting Call to be held on Monday, May 23rd at 4:30 pm EDT following the Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting

Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock

Announced positive topline results from Phase 2  SEISMiC study of istaroxime in early cardiogenic shock

Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates

Company to host conference call following the presentation Company to host conference call following the presentation

Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference

Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher Wednesday after the company announced topline results from the Phase 2 SEISMiC study of istaroxime in early cardiogenic shock. Istaroxime is a dual mechanism therapy designed to improve both systolic and diastolic cardiac.

Windtree Therapeutics Stock Is Trading Higher: Here's Why

Istaroxime significantly improved the systolic blood pressure profile Istaroxime significantly improved the systolic blood pressure profile

News for Windtree Therapeutics Stock (WINT)